Technical Analysis for ONCT - Oncternal Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical ONCT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 5.74% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.74% | |
| Bollinger Band Squeeze | Range Contraction | 5.74% | |
| Calm After Storm | Range Contraction | 5.74% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/08/2019
- Sector: Healthcare
- Industry: Biotechnology
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Solid Tumors Cancers Drug Development Hematologic Cancers Sarcoma
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Solid Tumors Cancers Drug Development Hematologic Cancers Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ONCT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 17.92 |
| 52 Week Low | 3.43 |
| Average Volume | 22,894 |
| 200-Day Moving Average | 6.5426 |
| 50-Day Moving Average | 5.2774 |
| 20-Day Moving Average | 5.6108 |
| 10-Day Moving Average | 5.696 |
| Average True Range | 0.3478 |
| ADX | 31.66 |
| +DI | 29.4262 |
| -DI | 9.6367 |
| Chandelier Exit (Long, 3 ATRs ) | 5.1616 |
| Chandelier Exit (Short, 3 ATRs ) | 5.3034 |
| Upper Bollinger Band | 6.0383 |
| Lower Bollinger Band | 5.1833 |
| Percent B (%b) | 1.05 |
| BandWidth | 15.238469 |
| MACD Line | 0.21 |
| MACD Signal Line | 0.1662 |
| MACD Histogram | 0.0438 |
| Fundamentals | Value |
|---|---|
| Market Cap | 97.63 Million |
| Num Shares | 16.1 Million |
| EPS | -1.71 |
| Price-to-Earnings (P/E) Ratio | -3.56 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 14.80 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.64 | ||||
| Resistance 3 (R3) | 6.60 | 6.39 | 6.54 | ||
| Resistance 2 (R2) | 6.39 | 6.25 | 6.40 | 6.51 | |
| Resistance 1 (R1) | 6.23 | 6.16 | 6.31 | 6.27 | 6.48 |
| Pivot Point | 6.02 | 6.02 | 6.06 | 6.03 | 6.02 |
| Support 1 (S1) | 5.86 | 5.88 | 5.94 | 5.90 | 5.68 |
| Support 2 (S2) | 5.65 | 5.79 | 5.66 | 5.65 | |
| Support 3 (S3) | 5.49 | 5.65 | 5.62 | ||
| Support 4 (S4) | 5.53 |
